Skip to main content

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma

Background

The phase 1 study of nivolumab, a fully human IgG4 programmed death-1 (PD-1) immune checkpoint inhibitor monoclonal antibody, showed promising antitumor activity in patients with advanced melanoma.

Materials and methods

This phase 3 study compared nivolumab vs dacarbazine in treatment-naïve patients with BRAF wild-type metastatic melanoma. Patients were randomized 1:1 to receive nivolumab 3 mg/kg every 2 weeks (Q2W) + placebo Q3W (n = 210) or dacarbazine 1000 mg/m2 Q3W + placebo Q2W (n = 208) until disease progression or unacceptable toxicity. Randomization was stratified by M-stage and programmed death ligand-1 (PD-L1) status. The primary endpoint was overall survival (OS). Patients were followed for up to 16.7 months at the time of data cutoff, which occurred 5.2 months after the first visit of the last patient randomized.

Results

The hazard ratio (HR) for death was 0.42 (99.79% CI 0.25–0.73; P < 0.0001) in favor of nivolumab, with 1-year OS rate 73% (95% CI, 66%–79%) for nivolumab vs 42% (95% CI, 33%–51%) for dacarbazine. Median OS was not reached for nivolumab and was 10.8 months for dacarbazine. Median progression-free survival (PFS) was 5.1 months for nivolumab and 2.2 months for dacarbazine (HR for death or progression 0.43, 95% CI 0.34–0.56; P < 0.0001). Objective response rate was 40% (84/210) vs 14% (29/208) for nivolumab and dacarbazine, respectively (P < 0.0001). Median duration of response was not reached for nivolumab and 6 months for dacarbazine. At the time of data cutoff, responses were ongoing in 86% (72/84) of nivolumab and 52% (15/29) of dacarbazine responders. PD-L1 positivity (using a 5% tumor cell surface staining cutoff) appeared to be associated with improved OS in the nivolumab arm (85% of PD-L1+ and 71% of PD-L1-/indeterminate patients alive at the time of last follow-up). Both PD-L1+ and PD-L1-/indeterminate patients receiving nivolumab had improved OS vs dacarbazine (un-stratified HR 0.30, 95% CI, 0.15–0.60 in PD-L1+ patients; 0.48, 95% CI, 0.32–0.71 in PD-L1-/indeterminate patient, both in favor of the nivolumab arm). The most common nivolumab-related adverse events (AEs) were fatigue, pruritus, and nausea. Drug-related grade 3–4 AEs were reported in 12% vs 18% of patients receiving nivolumab vs dacarbazine, respectively. AEs led to discontinuation in 7% and 12% of dacarbazine- vs nivolumab-treatment patients, respectively.

Conclusions

Compared to dacarbazine, nivolumab significantly improved OS and PFS in previously untreated patients with BRAF wild-type metastatic melanoma with an acceptable safety profile.

Clinical trial registration number

NCT01721772

Author information

Affiliations

Authors

Corresponding author

Correspondence to Paolo A Ascierto.

Rights and permissions

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.

The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Long, G.V., Atkinson, V., Ascierto, P.A. et al. Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma. J Transl Med 13, O6 (2015). https://doi.org/10.1186/1479-5876-13-S1-O6

Download citation

Keywords

  • Overall Survival
  • Dacarbazine
  • Immune Checkpoint
  • Checkpoint Inhibitor
  • Advanced Melanoma